205 related articles for article (PubMed ID: 16113602)
41. [Antitumor immune responses induced by idiotype-pulsed dendritic cells with cell-penetrating peptide vaccination in vivo].
Chang JH; Shi YX; Zhiang XS; Jiang WQ; Guan ZZ
Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):804-7. PubMed ID: 18396634
[TBL] [Abstract][Full Text] [Related]
42. Immunotherapy using dendritic cells against multiple myeloma: how to improve?
Nguyen-Pham TN; Lee YK; Kim HJ; Lee JJ
Clin Dev Immunol; 2012; 2012():397648. PubMed ID: 22481968
[TBL] [Abstract][Full Text] [Related]
43. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.
Hong S; Qian J; Li H; Yang J; Lu Y; Zheng Y; Yi Q
Cancer Immunol Immunother; 2012 Apr; 61(4):561-71. PubMed ID: 22002243
[TBL] [Abstract][Full Text] [Related]
44. Current vaccination strategies for the treatment of B-cell lymphoma and multiple myeloma.
Hollander N
Crit Rev Immunol; 2009; 29(5):399-418. PubMed ID: 20001888
[TBL] [Abstract][Full Text] [Related]
45. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
Li Y; Bendandi M; Deng Y; Dunbar C; Munshi N; Jagannath S; Kwak LW; Lyerly HK
Blood; 2000 Oct; 96(8):2828-33. PubMed ID: 11023518
[TBL] [Abstract][Full Text] [Related]
46. Generation of dendritic cells from positively selected CD14+ monocytes for anti-tumor immunotherapy.
Curti A; Isidori A; Ferri E; Terragna C; Neyroz P; Cellini C; Ratta M; Baccarani M; Lemoli RM
Leuk Lymphoma; 2004 Jul; 45(7):1419-28. PubMed ID: 15359643
[TBL] [Abstract][Full Text] [Related]
47. Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.
Wang S; Hong S; Wezeman M; Qian J; Yang J; Yi Q
Front Biosci; 2007 May; 12():3566-75. PubMed ID: 17485322
[TBL] [Abstract][Full Text] [Related]
48. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
49. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
50. Conjugation of lymphoma idiotype to CD40 antibody enhances lymphoma vaccine immunogenicity and antitumor effects in mice.
Carlring J; Szabo MJ; Dickinson R; De Leenheer E; Heath AW
Blood; 2012 Mar; 119(9):2056-65. PubMed ID: 22234700
[TBL] [Abstract][Full Text] [Related]
51. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
[TBL] [Abstract][Full Text] [Related]
52. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment.
Chen HW; Huang HI; Lee YP; Chen LL; Liu HK; Cheng ML; Tsai JP; Tao MH; Ting CC
Cancer Immunol Immunother; 2002 Aug; 51(6):341-8. PubMed ID: 12111122
[TBL] [Abstract][Full Text] [Related]
53. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
54. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
55. CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma.
Palomba ML; Roberts WK; Dao T; Manukian G; Guevara-Patiño JA; Wolchok JD; Scheinberg DA; Houghton AN
Clin Cancer Res; 2005 Jan; 11(1):370-9. PubMed ID: 15671568
[TBL] [Abstract][Full Text] [Related]
56. CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.
Hömberg N; Adam C; Riedel T; Brenner C; Flatley A; Röcken M; Mocikat R
Int J Cancer; 2014 Dec; 135(12):2825-33. PubMed ID: 24771135
[TBL] [Abstract][Full Text] [Related]
57. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
58. BCL1 lymphoma protection induced by idiotype DNA vaccination is entirely dependent on anti-idiotypic antibodies.
Cesco-Gaspere M; Benvenuti F; Burrone OR
Cancer Immunol Immunother; 2005 Apr; 54(4):351-8. PubMed ID: 15692846
[TBL] [Abstract][Full Text] [Related]
59. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
[TBL] [Abstract][Full Text] [Related]
60. Antigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma.
Li X; Zhang Z; Lin G; Gao Y; Yan Z; Yin H; Sun B; Wang F; Zhang H; Chen H; Cao D
Tumour Biol; 2016 Aug; 37(8):11267-78. PubMed ID: 26951511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
